Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
Status:
Recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well bevacizumab and atezolizumab with or without cobimetinib
work in treating patients with untreated melanoma that has spread to the brain (brain
metastases). Monoclonal antibodies, such as bevacizumab and atezolizumab, may interfere with
the ability of tumor cells to grow and spread. Cobimetinib may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. It is not yet known if giving
bevacizumab and atezolizumab with or without cobimetinib will work better in treating
patients with melanoma brain metastases.